Baird served as a joint bookrunning manager on this offering
AboutCastle Biosciences, Inc. (“Castle” or the “Company”) (NASDAQ:CSTL) recently completed an underwritten public offering of 4,600,000 shares of its common stock at a public offering price of $58.00 per share, which includes the exercise in full by the underwriters of their option to purchase an additional 600,000 shares of common stock. The transaction was upsized from the previously announced offering size of $125,000,000 of shares of common stock.
The Company expects to use the proceeds of this offering to advance the Company’s product pipeline, accelerate its R&D and medical affairs activities, provide additional support for marketed products, pay down debt and for working capital and other general corporate purposes.
Castle is a commercial-stage dermatologic cancer company focused on providing physicians and their patients with personalized, clinically actionable genomic information to make more accurate treatment decisions. The Company is headquartered in Friendswood, Texas.
CONTACT US TO LEARN MORE
- December 2020
- Castle Biosciences, Inc.
- Target Location
- North America